1,090 results
8-K
EX-99.1
TEVA
Teva- Pharmaceutical Industries Ltd.
15 May 24
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
8:30am
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based
8-K
EX-99.1
TEVA
Teva- Pharmaceutical Industries Ltd.
8 May 24
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
7:01am
to the first quarter of 2023, mainly due to lower litigation fees in the first quarter of 2024.
Operating loss in the first quarter of 2024 was $218 million … consisted of $64 million attributable to an update to the estimated settlement provision for the Company’s opioid litigation (mainly the effect
8-K
EX-99.1
4bi10gzr2lhci
31 Jan 24
Results of Operations and Financial Condition
7:00am
8-K
EX-99.1
cnmeaxt488g69t lzd8
8 Nov 23
2023 revenues outlook revised to $15.1 - $15.5 billion from $15.0 - $15.4 billion
7:01am
8-K
qzlzqxtohue07
4 Oct 23
Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment
6:05am
8-K
EX-99.1
ky6tm62d6ucgrye6c
4 Oct 23
Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment
6:05am
8-K
EX-99.1
0f6 pvisxbtgyrh1w
28 Sep 23
Teva Announces Changes to Executive Management Team
4:05pm
8-K
EX-10.1
drszofedjpsqoo
24 Aug 23
Entry into a Material Definitive Agreement
7:30am
8-K
EX-99.1
t0a9w1hq0 4xybf
24 Aug 23
Entry into a Material Definitive Agreement
7:30am
8-K
skv4n17yjmp5pjo5
24 Aug 23
Entry into a Material Definitive Agreement
7:30am
8-K
EX-99.1
p99luh 0sbytd8qdr4
2 Aug 23
Results of Operations and Financial Condition
7:00am
8-K
bkn5rh d2svh
8 Jun 23
Teva Concludes Nationwide Opioids Settlement Agreement
8:30am